依达拉奉治疗急性脑梗死的临床观察

目的观察依达拉奉治疗急性脑梗死的临床疗效及安全性。方法选择发病48h以内入院的急性脑梗死患者60例，随机分为治疗组（30例）和对照组（30例）。治疗组采用依达拉奉30mg加入生理盐水100ml静脉点滴，2次／d，连续7～10d。对照组给予丹参注射液20ml加入生理盐水250ml静脉点滴，1次／d，连续7～10d。两组在治疗前后根据第四届全国脑血管病学术会议制定的脑卒中患者临床神经功能缺损评分和日常生活能力量表评分标准进行评分，判断其疗效并观察其不良反应。结果治疗组患者神经功能缺损评分明显下降，日常生活能力有较大的提高，治疗组疗效明显优于对照组。依达拉奉组无明显不良反应。结论依达拉奉用于治疗急性脑梗死安全有效。

Clinical observation on Edaravone in treatment of acute cerebral infarction

Objective To assess the clinical efficacy and safety of Edaravone in treatment of patients with acute cerebral infarction. Methods Sixty patients with acute cerebral infarction admitted within 48 hours of onset were enrolled in this study, they were randomly allocated into therapeutic group and control group, 30 cases in each group. Patients in therapeutic group received intravenously Edaravone 30 mg in 100 ml normal saline,twice a day for 7 - 10 days. Patients in control group received intravenously FuFangDanShan injection of 20 ml plus normal saline 250 ml, once daily for 7 - 10 days. The clinical conditions of patients were evaluated according to nervous functional defect grades and activities of daily living established in 4th Conference of Cerebral Vascular Disease before and after treatment. Their clinical effectiveness and side effects were observed. Results The activities of daily living of patients were markedly improved and the grades of nervous functional defect in patients of Edaravone group were decreased distinctly in comparison with those before treatment （ P 〈0.01 ）. The efficacy in therapeutic group was obviously superior to that Of control group （ P 〈 0.01 ）. There was no significant side effect seen in patients of Edaravone group. Conclusion Edaravone is effective and safe in treatment of patients with acute cerebral infarction.